Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
US10577344B2 · kind B2 · utility
0Cited by
11References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 27, 2017 |
| Grant date | Mar 3, 2020 |
| Priority date | — |
| Expiry date | Nov 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.